In a 2018 study, where researchers evaluated the efficacy of anti-vascular endothelial growth factor (VEGF) bevacizumab in resected high-risk stage II and III melanoma patients randomly selected from the AVAST-M trial [87] it was revealed that patients who exhibited ctDNA after receiving curative surgery experienced a reduction in their disease-free interval (DFI) and OS compared to those who did not exhibit ctDNA [88]. Here, VEGFA is linked to melanoma.